U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07738107) titled 'ATR 1072 in Participants With PRKAG2 Syndrome' on June 26.
Brief Summary: ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Cardiac Glycogenosis
Cardiomyopathy
Hypertrophic
Wolff-Parkinson-White Syndrome
Intervention:
DRUG: ATR 1072
ATR 1072 is an investigational therapy that delivers an siRNA to reduce PRKAG2 gene expression. Administered as an i...